Akero

Akero is a pioneering clinical-stage biopharmaceutical software innovator of innovative therapies for severe metabolic diseases, most notably metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). Founded in January 2017 by Jonathan Young and Timothy Rolph, the company has rapidly established itself among the leaders in the metabolic disease therapeutics landscape, leveraging scientific rigor and translational medicine to address a major unmet medical need. With a mission centered on delivering transformational treatments for conditions that have limited or no effective existing options, Akero’s portfolio is anchored by its flagship compound, efruxifermin (EFX), an engineered analog of fibroblast growth factor 21 (FGF21). Efruxifermin (EFX), licensed from Amgen, is at the heart of Akero's R&D strategy and commercialization ambition. EFX is specifically designed to treat MASH, a severe progressive liver condition driven by metabolic dysfunction, fibrosis, and chronic inflammation. The disease remains one of the most significant unmet needs in metabolic medicine, with limited approved treatment options and a global patient population expected to rise in the coming years. Akero's scientific approach focuses on restoring systemic metabolic balance rather than merely addressing symptomatology, aiming for disease modification that can change long-term health trajectories for affected patients. The company’s growth and market visibility have been underscored by a series of substantial funding rounds and a successful IPO. As of mid-2025, Akero’s market capitalization stands near $1.7 billion, supported by strong institutional backing and a robust cash reserve exceeding $700 million, which sustains its R&D efforts and clinical programs. The company’s capital efficiency and financial stability align with the industry’s best practices for early-to-mid-stage biotech firms, though Akero has not yet generated commercial revenues as is typical for this stage of drug development. Clinical data positions EFX as one of the front-runners in the MASH/NASH therapeutic class. In multiple Phase 2 studies, including the prominent HARMONY trial, EFX demonstrated its potential to resolve MASH and reverse varying degrees of liver fibrosis—even advancing some patients with cirrhosis to lower fibrosis stages, which is a critical milestone for liver disease therapies. Beyond fibrosis, EFX has shown consistent improvement in key metabolic parameters such as insulin sensitivity and lipid profiles, suggesting additional long-term cardiometabolic benefits. The pipeline’s continued advancement hinges on Phase 3 SYNCHRONY program results, which, if positive, could set a new standard in MASH care and unlock a multi-billion-dollar market. Akero's business model centers on internal R&D execution and organic product expansion, rather than via acquisition. The company continues to build its scientific team and expand its clinical and regulatory capabilities to shepherd EFX through pivotal studies and toward commercial launch. Akero’s management emphasizes a culture of integrity, scientific curiosity, and a commitment to patient-centered innovation. This is reflected in its engagement with clinical trial participants, medical professionals, and the wider research community, as well as its transparency through frequent scientific publications and conference presentations.

Akero Therapeutics holds a pronounced competitive edge in the race to develop effective therapies for metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH, due to its best-in-class candidate, efruxifermin (EFX), and a series of clinical and strategic differentiators within a crowded and challenging therapeutic landscape. The most significant factor that sets Akero apart from its competitors is the scientific profile and groundbreaking clinical results of EFX. Unlike other investigational and even marketed metabolic therapies—such as GLP-1 agonists from Novo Nordisk and Eli Lilly that primarily target weight loss—EFX is a fibroblast growth factor 21 (FGF21) analog specifically engineered to provide sustained metabolic and anti-fibrotic activity in both the liver and adipose tissue. This dual mechanism addresses the root causes and consequences of MASH, targeting not just the metabolic dysfunction that underpins disease progression, but also reversing the fibrosis and cellular stress that lead to liver cirrhosis and end-stage organ failure. What truly cements Akero’s leadership is the clinical validation witnessed in multiple trials: most notably, EFX became the first therapy in its class to demonstrate statistically significant reversal of cirrhosis in patients with compensated MASH (stage F4 fibrosis). Data from the company’s 96-week Phase 2b trial showed 39% of patients treated with EFX experienced reversal of cirrhosis with no worsening of MASH—compared to just 15% with placebo—a remarkable result unmatched by other therapies in development. Importantly, these outcomes were achieved in patients who were not also using GLP-1 weight-loss medications, indicating the direct efficacy of EFX on liver pathology independent of weight loss. For trial investigators and leading hepatologists, this breakthrough represents a watershed moment, as previous treatment options for advanced MASH could only slow progression, not reverse scarring.

• Small Businesses (1-99)
• Mid Market (100-500)
• Enterprise (500+)